Holen Sie sich die Stockscreener-App
7.23
0.84%
0.06
Handel nachbörslich:
7.23
Schlusskurs vom Vortag:
$7.17
Offen:
$7.16
24-Stunden-Volumen:
210.07K
Relative Volume:
0.82
Marktkapitalisierung:
$368.00M
Einnahmen:
$227.18M
Nettoeinkommen (Verlust:
$24.38M
KGV:
15.14
EPS:
0.4774
Netto-Cashflow:
$53.60M
1W Leistung:
+2.99%
1M Leistung:
+4.48%
6M Leistung:
+29.57%
1J Leistung:
+110.79%
1-Tages-Spanne:
$7.10
$7.31
1-Wochen-Bereich:
$6.96
$7.45
52-Wochen-Spanne:
$3.03
$7.8983
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.23 | 359.86M | 227.18M | 24.38M | 53.60M | 0.4774 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology director Jay Moyes sells $158k in stock - Investing.com UK
Puma Biotechnology director Adrian Senderowicz sells $194,310 in stock - Investing.com UK
Puma biotechnology director Troy Wilson sells $77,748 of stock By Investing.com - Investing.com Nigeria
PUMA Biotechnology (PBYI) director trades shares, receives 27,000 RSUs grant - Stock Titan
Puma Biotechnology (PBYI) director gets 27K RSUs, sells 8.1K shares under 10b5-1 plan - Stock Titan
Puma biotechnology director Brian Stuglik sells $58,311 in stock By Investing.com - Investing.com UK
Puma Biotechnology (PBYI) Slides 2.5% as Support Test Looms Near $6.79MFI Divergence - newsline.com
Puma Biotechnology stock rises 19% in 3 months: Here's why - MSN
[144] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - TradingView
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 - BioSpace
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule - TradingView
Puma Biotechnology PBYI Edges Higher Amidst Key Support and Resistance LevelsThe Legal Advocate - The Legal Advocate
Puma Biotechnology (PBYI) Edges Higher Amidst Key Support and Resistance LevelsPercent Below MA - newsline.com
PBYI Stock Price, Quote & Chart | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill
PBYI Stock Inches Higher: The Quiet Puma Biotechnology Signal Investors Are Watching - Bez Kabli
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Puma Biotechnology's (NASDAQ:PBYI) Soft Earnings Are Actually Better Than They Appear - 富途牛牛
PBYI Q1 earnings & sales beat estimates, 2026 guidance raised - MSN
Puma forecasts $202M-$206M in 2026 NERLYNX net product revenue while planning alisertib dose escalation and new Lung2 trial - MSN
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings - Sahm
Puma Biotechnology Reveal Hidden Strength Amid Rising Market Focus - Kalkine Media
Puma Biotechnology IncCommon Stock (NQ: PBYI - FinancialContent
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
TradingKey - TradingKey
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00 - Yahoo Finance
Puma Biotechnology Reports Q1 2026 Revenue and Positive Outlook - HarianBasis.co
Puma Biotechnology Q1 2026 Financial Results: Revenue, Net Loss, and Key Risk Disclosures - Minichart
PBYI Puma Biotechnology beats Q1 earnings estimates by 69.8%, shares rise 3.17% on positive outlook.Stability Report - newser.com
Puma Biotechnology Q1 Earnings Call Highlights - sharewise.com
Puma (PBYI) Q1 2026 Earnings Call Transcript - The Globe and Mail
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised - The Globe and Mail
Puma Biotechnology, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-05-08 - Seeking Alpha
Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Puma Biotechnology Reports First Quarter 2026 Financial Results - BioSpace
PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) Beats Q1 Estimates, Raises Full-Year Guidance - ChartMill
Earnings call transcript: Puma Biotech Q1 2026 misses EPS, revenue forecasts - Investing.com
Earnings call transcript: Puma Biotech Q1 2026 misses EPS, revenue forecasts By Investing.com - Investing.com South Africa
PBYI: Q1 2026 NERLYNX revenue dropped 3% year-over-year, with 78% of patients on reduced doses - TradingView
Puma Biotechnology : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Puma Biotech: Q1 Earnings Snapshot - kens5.com
MSN Money - MSN
Puma Biotechnology Q1 revenue falls on weaker NERLYNX sales; raises 2026 outlook - TradingView
Puma Biotechnology (NASDAQ: PBYI) swings to Q1 2026 loss - Stock Titan
Puma Biotechnology (NASDAQ: PBYI) raises 2026 guidance and eliminates debt - Stock Titan
Cancer drug NERLYNX demand pushes Puma to raise 2026 outlook - Stock Titan
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stuglik Brian M | Director |
Jun 12 '26 |
Sale |
7.20 |
8,100 |
58,311 |
113,858 |
| Senderowicz Adrian | Director |
Jun 12 '26 |
Sale |
7.20 |
27,000 |
194,311 |
27,000 |
| MOYES JAY M | Director |
Jun 12 '26 |
Sale |
7.22 |
22,000 |
158,796 |
58,322 |
| Dorval Allison | Director |
Jun 12 '26 |
Sale |
7.20 |
11,610 |
83,579 |
90,780 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):